,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['breast']
wonderful plenary session today #asco22 standing ovation well deserved for destiny-breast 04 randomized phase 3 study, with results showing potential improvements in pfs and os of almost 50% of patients with low her2 expressing tumors 
MBA,BS,BA,CCRC | Hematology/Oncology Research Supervisor| Scientific Writer| Advocate for Health Equity